Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma

Vox Sanguinis

Volumn 85, Issue 2, 2003, Pages 88-95

  Riedler, G F ^a   Haycox, A R ^c   Duggan, A K ^b   Dakin, Helen A ^b  

^a Regionales Blutspendezentrum   (Switzerland)

^b Decision Resources Group   (United Kingdom)

^c NONE

Author keywords

Cost effectiveness analysis; Fresh frozen plasma; Solvent detergent treated fresh frozen plasma; Transfusion reactions

Indexed keywords

DETERGENT; FRESH FROZEN PLASMA; SOLVENT;

ADOLESCENT; ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLEEDING; BLOOD DONOR; BLOOD TRANSFUSION REACTION; CHILD; COST EFFECTIVENESS ANALYSIS; FEMALE; HEMOLYSIS; HUMAN; INFECTIOUS COMPLICATION; MAJOR CLINICAL STUDY; MALE; PLASMA TRANSFUSION; PRIORITY JOURNAL; PROGNOSIS; RECIPIENT; TIME SERIES ANALYSIS; VIRUS TRANSMISSION;

ALGORITHMS; BLOOD TRANSFUSION; COST-BENEFIT ANALYSIS; DETERGENTS; HUMANS; MODELS, ECONOMIC; PLASMA; SOLVENTS; STERILIZATION;

EID: 0041639518     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.2003.00329.x     Document Type: Article

References (49)

1. Popovsky MA, Abel MD, Moore SB: Transfusion-related acute lung injury associated with passive transfer of antileukocyte antibodies. Am Rev Respir Dis 1983; 128:185-189
2. Serious Hazards of Transfusion: (SHOT) - Annual Report 2000-2001. Manchester, the Serious Hazards of Transfusion Steering Group, 2002
3. Sharma AD, Sreeram G, Erb T, Grocott HP: Solvent-detergent-treated fresh frozen plasma: a superior alternative to standard fresh frozen plasma? J Cardiothorac Vasc Anesth 2000; 14:712-717
4. Biesert L, Suhartono H: Solvent/detergent treatment of human plasma - a very robust method for virus inactivation. Validated virus safety of OCTAPLAS. Vox Sang 1998; 74:207-212
5. Horowitz B, Lazo A, Grossberg H, Page G, Lippin A, Swan G: Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang 1998; 74:203-206
6. Baudoux E, Margraff U, Coenen A, Jacobs X, Strivay M, Lungu C, Sondag-Thull D: Hemovigilance. clinical tolerance of solvent-detergent treated plasma. Vox Sang 1998; 74:237-239
7. AuBuchon JP, Birkmeyer JD: Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply. JAMA 1994; 272:1210-1214
8. Pereira A: Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion 1999; 39:479-487
9. Jackson BR, AuBuchon JP, Birkmeyer JD: Update of cost-effectiveness analysis for solvent-detergent-treated plasma. JAMA 1999; 282:329
10. Popovsky MA: Transfusion and lung injury. Transfus Clin Biol 2001; 8:272-277
11. Sloop GD, Friedberg RC: Complications of blood transfusion. How to recognize and respond to noninfectious reactions. Postgrad Med 1995; 98:159-162,166,169-72
12. Silliman CC, Paterson AJ, Dickey WO, Stroneck DF, Popovsky MA, Caldwell SA, Ambruso DR: The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study. Transfusion 1997; 37:719-726
13. Popovsky MA, Moore SB: Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985; 25:573-577
14. Weber JG, Warner MA, Moore SB: What is the incidence of perioperative transfusion-related acute lung injury? Anesthesiology 1995; 82:789
15. Silliman CC: Transfusion-related acute lung injury. Transfus Med Rev 1999; 13:177-186
16. Popovsky MA, Chaplin HC Jr, Moore SB: Transfusion-related acute lung injury, a neglected, serious complication of hemotherapy. Transfusion 1992; 32:589-592
17. Bux J, Becker F, Seeger W, Kilpatrick D, Chapman J, Waters A: Transfusion-related acute lung injury due to HLA-A2-specific antibodies in recipient and NB1-specific antibodies in donor blood. Br J Haematol 1996; 93:707-713
18. Snyder EL: Transfusion reactions; in Hoffman R (ed.): Hematology: Basic Principles and Practice. New York, Churchill Livingstone, 1995:2045-2053
19. Whyte GS: The transfused population of Canterbury, New Zealand, and its mortality. Vox Sang 1988; 54:65-70
20. Vamvakas EC, Taswell HF: Long-term survival after blood transfusion. Transfusion 1994; 34:471-477
21. Vamvakas EC, Moore SB: Length of survival after perioperative transfusion. Transfus Med 1997; 7:115-121
22. Office for National Statistics: Expectation of Life (In Years) at Birth Selected Ages, 1971 Onwards: Population Trends 108. London, Office for National Statistics, 2002 [http://www.statistics.gov.uk]
23. Department of Health: National Schedule of Reference Costs -NHS Trust Clinical Care Services Data, 2001. London, Department of Health, 2002
24. Lapins DL, Urdaneta ME, Barrett J, Hamel EC, Duong PT, Markson LE: Costs of care for HIV infection in a managed care population from 1995 to 1997 Am J Manag Care 2000; 6:973-981
25. Sonnenberg FA, Gregory P, Yomtovian R, Russell LB, Tierney W, Kosmin M, Carson JL: The cost-effectiveness of autologous transfusion revisited: implications of an increased risk of bacterial infection with allogeneic transfusion. Transfusion 1999; 39:808-817
26. Netten A, Rees A, Harrison G: Unit Costs of Health and Social Care. Canterbury, UK, PSSRU Personal Social Services Research Unit, 2001
27. British Medical Association: British National Formulary (BNF), no. 43. London, British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2002
28. Wood CGA, Whittet S, Bradbeer CS: ABC of palliative care. HIV infection and AIDS. BMJ 1997; 315:1433-1436
29. Pereira A: Health and economic consequences of HCV lookback. Transfusion 2001; 41:832-839
30. HM Treasury: The Green Book: Appraisal and Evaluation in Central Government. London, TSO, 2003
31. Dodd RY: Adverse consequences of blood transfusion: quantitative risk estimates; in Nance ST (ed.): Blood Supply: Risks, Perceptions and Prospects for the Future. Bethesda, American Association of Blood Banks, 1994
32. Donegan E, Lee H, Operskalski EA, Shaw GM, Kleinman SH, Busch MP, Stevens CE, Schiff ER, Nowicki MJ, Hollingsworth CG: Transfusion transmission of retroviruses: human T-lymphotropic virus types I and II compared with human immunodeficiency virus type 1. Transfusion 1994; 34:478-483
33. Rollag H, Solheim BG, Svennevig JL: Viral safety of blood derivatives by immune neutralization. Vox Sang 1998; 74:213-217
34. Allain JP: Emerging viral infections relevant to transfusion medicine. Blood Rev 2000; 14:173-181
35. Tuveri R, Jaffredo F, Lunel F, Nalpa B, Pol S, Feray C, Marcellin P, Thibault V, Delagneau JF, Opolon P, Scarpa B, Brechot C, Thiers V: Impact of TT virus infection in acute and chronic, viral- and non viral-related liver diseases. J Hepatol 2000; 33:121-127
36. Vamvakas EC: Risk of transmission of Creutzfeldt-Jakob disease by transfusion of blood, plasma, and plasma derivatives. J Clin Apheresis 1999; 14:135-143
37. Sivakumaran M: Universal leucodepletion to reduce the risk of transmission of new-variant Creutzfeldt-Jakob disease. Br J Haematol 2000; 110:234
38. Birkmeyer JD, Goodnough LT, AuBuchon JP, Noordsij PG, Littenberg B: The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion 1993; 33:544-551
39. Birkmeyer JD, AuBuchon JP, Littenberg B, O'Connor GT, Nease RF Jr, Nugent WC, Goodnough LT: Cost-effectiveness of preoperative autologous donation in coronary artery bypass grafting. Ann Thorac Surg 1994; 57:161-168; discussion 168-9
40. Pereira A, Sanz C: A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols. Transfusion 2000; 40:1182-1191
41. Gow PJ, Mutimer D: Treatment of chronic hepatitis. BMJ 2001; 323:1164-1167
42. Dusheiko GM, Roberts JA: Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995; 22:1863-1873
43. Brophy M, Bodger S, Guta A, Sinnott PJ: HLA-specific antibodies in single unit and pooled fresh plasma samples. Transfus Med 2001; 11:013
44. Tynell E, Norda R, Shanwell A, Bjorkman A: Long-term survival in transfusion recipients in Sweden 1993. Transfusion 2001; 41:251-255
45. Susal C, Opelz G: Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002; 73:1269-1273
46. Kleinman SH, Busch MP: The risks of transfusion-transmitted infection: direct estimation and mathematical modelling. Baillieres Best Pract Res Clin Haematol 2000; 13:631-649
47. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334:1685-1690
48. Soldan K, Ramsay M, Collins M: Acute hepatitis B infection associated with blood transfusion in England and Wales, 1991-7: review of database. BMJ 1999; 318:95
49. Centers for Disease Control: Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues and semen for evidence of hepatitis B and hepatitis C. MMWR 1991; 40:1-17